Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT3A | Q9Y6K1 | 8/20 | 0.51 |
| ▸ | DNMT1 | P26358 | 7/20 | 0.51 |
| ▸ | APP | P05067 | 3/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18103376 | 0.91 | DNMT3A (0.50) | DNMT3ADNMT1APPPIK3CDPIK3R1 | |
| SCHEMBL17994863 | 0.85 | DNMT3A (0.66) | DNMT3ADNMT1APPPIK3CDPIK3R1 | |
| SCHEMBL17994889 | 0.84 | DNMT3A (0.67) | DNMT3ADNMT1APPPIK3CDPIK3R1 | |
| SCHEMBL18103379 | 0.83 | SLC2A1 (0.57) | DNMT3ADNMT1APP | |
| SCHEMBL18095971 | 0.83 | DNMT3A (0.61) | DNMT3ADNMT1APP | |
| SCHEMBL18095969 | 0.82 | APP (0.60) | APPPIK3CDPIK3R1PDE5ACYP1A2 | |
| SCHEMBL18095968 | 0.81 | DNMT3A (0.80) | DNMT3ADNMT1APP | |
| SCHEMBL20113704 | 0.80 | DNMT3A (0.68) | DNMT3ADNMT1 | |
| SCHEMBL16596213 | 0.76 | DNMT3A (0.64) | DNMT3ADNMT1APPPIK3CDPIK3R1 | |
| SCHEMBL18095967 | 0.75 | APP (0.62) | APPPIK3CDPIK3R1PDE5ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118717-A1 | Substituted Quinazoline Derivatives as DNA Methyltransferase Inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118717-A1 | Substituted Quinazoline Derivatives as DNA Methyltransferase Inhibitors | DNMT1, DNMT3A, DNMT3B | DNMT3A 2/4885DNMT1 1/4885APP 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.